Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
12.78
-0.29 (-2.22%)
At close: Feb 13, 2026, 4:00 PM EST
12.79
+0.01 (0.08%)
After-hours: Feb 13, 2026, 7:30 PM EST
Vor Biopharma Stock Forecast
VOR's stock price has decreased by -53.7% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 9 analysts that cover Vor Biopharma stock have a consensus rating of "Buy" and an average price target of $64.78, which forecasts a 406.89% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $160.
Price Target: $64.78 (+406.89%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Vor Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 3 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 7 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +291.24% | Jan 9, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $43 → $40 | Buy | Maintains | $43 → $40 | +212.99% | Dec 19, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Dec 17, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $43 | Buy | Initiates | $43 | +236.46% | Dec 9, 2025 |
| Wedbush | Wedbush | Hold Initiates $9 | Hold | Initiates | $9 | -29.58% | Nov 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-128.79
from -34.03
EPS Next Year
-5.51
from -128.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -36.82 | -1.46 | ||||
| Avg | -128.79 | -5.51 | ||||
| Low | -252.73 | -10.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.